ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of motion correction on myocardial [Medical physics · 2026Article
Corrections and comments
- Update of
Authors and funding
23 authors.
Funding
Abstract
purposeAdvances in cancer therapy have improved survival but increased the risk of treatment-related cardiotoxicity, which remains difficult to detect early with existing biomarkers. [18F]F-AraG is a positron emission tomography (PET) tracer that targets cells with active mitochondrial biogenesis, including cardiomyocytes and activated T cells, and may enable concurrent assessment of cardiac involvement and therapy-associated immune activity. This study evaluated whether [18F]F-AraG PET can serve as an early imaging biomarker of cardiac effects across different cancer therapies. EXPERIMENTAL
designTwenty-six healthy subjects underwent [18F]F-AraG PET to establish baseline myocardial uptake. Seven patients with stage III melanoma and 10 with advanced non-small cell lung cancer were imaged before and after immunotherapy. Myocardial uptake (SUVmax, SUVmean, and SUVtotal) was quantified in the left ventricle (LV) and right ventricle (RV), with LV regional uptake analyzed using a 17-segment model. Myocardial uptake was examined in relation to abnormal cardiac status in a subset of patients with available electrocardiogram (ECG) data. Associations between cardiac uptake, mitochondrial content, and PGC1α expression were evaluated.
resultsHealthy myocardium demonstrated consistent and spatially uniform [18F]F-AraG uptake across age and sex, with higher uptake in the LV than in the RV. Conventional therapy was associated with increased global myocardial uptake, whereas immunotherapy was associated with additional heterogeneous and focal myocardial uptake. Altered myocardial uptake patterns were observed in patients with ECG abnormalities.
conclusions[18F]F-AraG PET detects therapy-associated changes in myocardial tracer uptake following cancer treatment. These findings support its potential utility as a noninvasive imaging approach for the early evaluation of cardiac effects in patients receiving cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.